Recombinant von Willebrand factor: potential therapeutic use

Area of Science:

• Biotechnology
• Hematology
• Protein Engineering

Background:

• Plasma-derived von Willebrand factor (vWF) concentrates have limitations including degradation, variable multimer composition, and donor dependence.
• Recombinant vWF (rec-vWF) presents a novel therapeutic avenue for von Willebrand disease (vWD).

Purpose of the Study:

• To characterize the structural and functional properties of rec-vWF.
• To evaluate the therapeutic efficacy of rec-vWF in preclinical models of vWD.

Main Methods:

• Production of rec-vWF via continuous fermentation of transformed mammalian cells.
• Isolation of rec-vWF fractions with varying multimerization degrees.
• Structural analysis (post-translational modifications) and functional assays (platelet/collagen/FVIII binding).
• In vivo studies in vWF-deficient mice, dogs, and pigs.

Main Results:

• Rec-vWF undergoes comparable post-translational modifications (multimerization, pro-peptide processing, glycosylation) to plasma-derived vWF.
• Functional assays confirmed platelet binding, aggregation, collagen binding, and FVIII binding activities, which correlated with multimer size.
• In vivo administration of rec-vWF significantly reduced bleeding in mice and increased endogenous FVIII levels in dogs and pigs.
• Rec-vWF demonstrated resistance to proteolytic degradation in circulation.

Conclusions:

• Rec-vWF exhibits structural and functional characteristics similar to plasma-derived vWF.
• Rec-vWF shows significant therapeutic potential for correcting vWF levels and stabilizing FVIII in vivo.
• Rec-vWF overcomes limitations associated with plasma-derived vWF concentrates, offering a viable alternative treatment for vWD.